UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 20.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 147,684 shares of the biopharmaceutical company’s stock after selling 38,376 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.09% of Ocular Therapeutix worth $1,285,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Atlas Capital Advisors LLC acquired a new position in shares of Ocular Therapeutix in the second quarter valued at approximately $34,000. Amalgamated Bank grew its position in Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 1,015 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Ocular Therapeutix in the 3rd quarter worth $70,000. Finally, Algert Global LLC purchased a new stake in shares of Ocular Therapeutix in the second quarter valued at about $69,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on OCUL. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. Scotiabank assumed coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Ocular Therapeutix presently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Ocular Therapeutix Trading Up 0.4 %

OCUL stock opened at $9.02 on Wednesday. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -6.93 and a beta of 1.19. Ocular Therapeutix, Inc. has a 52 week low of $3.63 and a 52 week high of $11.77. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The business has a fifty day simple moving average of $10.05 and a 200-day simple moving average of $8.54.

Insider Buying and Selling

In other news, insider Jeffrey S. Heier sold 2,948 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the sale, the insider now owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.50% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.